Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MUROMONAB-CD3 for Bone marrow conditioning regimen: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where MUROMONAB-CD3 was used for Bone marrow conditioning regimen.

Most Reported Side Effects for MUROMONAB-CD3

Side Effect Reports % Deaths Hosp.
Post transplant lymphoproliferative disorder 22 19.3% 3 14
Infection 16 14.0% 6 3
Cytomegalovirus infection 13 11.4% 5 4
Cytomegalovirus oesophagitis 10 8.8% 1 0
Drug resistance 10 8.8% 1 0
Duodenitis 10 8.8% 1 1
Gastritis 10 8.8% 1 1
Weight decreased 10 8.8% 1 0
Chest pain 9 7.9% 1 0
Cytomegalovirus chorioretinitis 9 7.9% 0 0
Cytomegalovirus infection reactivation 9 7.9% 1 0
Encephalitis 9 7.9% 1 0
Gastric fistula 9 7.9% 1 0
Gastric ulcer 9 7.9% 1 0
Gastrointestinal ulcer 9 7.9% 1 0

Other Indications for MUROMONAB-CD3

Immunosuppressant drug therapy (38) Prophylaxis against transplant rejection (20) Prophylaxis against graft versus host disease (13) Immunosuppression (12) Transplant rejection (12) Product used for unknown indication (11) Allogenic stem cell transplantation (5)

Other Drugs Used for Bone marrow conditioning regimen

FLUDARABINE (6,080) BUSULFAN (4,669) CYCLOPHOSPHAMIDE (4,485) MELPHALAN (2,368) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (1,884) THIOTEPA (1,551) ALEMTUZUMAB (1,122) ETOPOSIDE (936) CYTARABINE (833) THYMOCYTE IMMUNE GLOBULIN NOS (742)

Related Pages

MUROMONAB-CD3 Full Profile All Bone marrow conditioning regimen Drugs MUROMONAB-CD3 Demographics MUROMONAB-CD3 Timeline